Fig. 2From: Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trialPost-COVID neuropsychological symptoms at 12 weeks after initial infection in fluvoxamine and placebo groupsBack to article page